INNO-GENE SA ZY -10 (WQ3) - Net Assets
Based on the latest financial reports, INNO-GENE SA ZY -10 (WQ3) has net assets worth €17.55 Million EUR (≈ $20.51 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€25.00 Million ≈ $29.23 Million USD) and total liabilities (€7.45 Million ≈ $8.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check WQ3 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €17.55 Million |
| % of Total Assets | 70.19% |
| Annual Growth Rate | 31.91% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 318.33 |
INNO-GENE SA ZY -10 - Net Assets Trend (2021–2024)
This chart illustrates how INNO-GENE SA ZY -10's net assets have evolved over time, based on quarterly financial data. Also explore INNO-GENE SA ZY -10 balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for INNO-GENE SA ZY -10 (2021–2024)
The table below shows the annual net assets of INNO-GENE SA ZY -10 from 2021 to 2024. For live valuation and market cap data, see INNO-GENE SA ZY -10 market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €18.02 Million ≈ $21.06 Million |
+638.80% |
| 2023-12-31 | €2.44 Million ≈ $2.85 Million |
-69.71% |
| 2022-12-31 | €8.05 Million ≈ $9.41 Million |
+2.60% |
| 2021-12-31 | €7.85 Million ≈ $9.17 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INNO-GENE SA ZY -10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 540254509.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €25.20 Million | 139.87% |
| Total Equity | €18.02 Million | 100.00% |
INNO-GENE SA ZY -10 Competitors by Market Cap
The table below lists competitors of INNO-GENE SA ZY -10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guardforce AI Co Ltd
NASDAQ:GFAI
|
$14.91 Million |
|
Batavia Prosperindo Trans Tbk PT
JK:BPTR
|
$14.91 Million |
|
Wise Group AB
ST:WISE
|
$14.91 Million |
|
BALAXI PHARMACEUTICALS LIMITED
NSE:BALAXI
|
$14.92 Million |
|
Intrasoft Technologies Limited
NSE:ISFT
|
$14.87 Million |
|
GigaMedia Limited
F:GIFN
|
$14.87 Million |
|
Applied Therapeutics Inc
NASDAQ:APLT
|
$14.86 Million |
|
Mason Capital Corporation
KQ:021880
|
$14.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INNO-GENE SA ZY -10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,438,485 to 18,015,611, a change of 15,577,126 (638.8%).
- Net income of 18,846 contributed positively to equity growth.
- New share issuances of 316,688 increased equity.
- Other factors increased equity by 15,241,591.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €18.85K | +0.1% |
| Share Issuances | €316.69K | +1.76% |
| Other Changes | €15.24 Million | +84.6% |
| Total Change | €- | 638.80% |
Book Value vs Market Value Analysis
This analysis compares INNO-GENE SA ZY -10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.71x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.28x to 0.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.38 | €0.38 | x |
| 2022-12-31 | €1.41 | €0.38 | x |
| 2023-12-31 | €0.43 | €0.38 | x |
| 2024-12-31 | €0.54 | €0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INNO-GENE SA ZY -10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.57%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.36x
- Recent ROE (0.10%) is above the historical average (-43.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 76.86% | 20.14% | 2.23x | 1.71x | €5.25 Million |
| 2022 | 3.91% | 1.92% | 1.60x | 1.28x | €-490.10K |
| 2023 | -255.08% | -551.44% | 0.20x | 2.29x | €-6.46 Million |
| 2024 | 0.10% | 0.57% | 0.13x | 1.36x | €-1.78 Million |
Industry Comparison
This section compares INNO-GENE SA ZY -10's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $794,972,119
- Average return on equity (ROE) among peers: -36.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INNO-GENE SA ZY -10 (WQ3) | €17.55 Million | 76.86% | 0.42x | $14.88 Million |
| LIFELINE SPAC I OYJ A EO1 (0CD) | $108.00 Million | -8.98% | 0.09x | $261.36 Million |
| GRAPHENE MANUFACT.GROUP (0GF) | $2.03 Million | 0.00% | 1.43x | $185.36 Million |
| Orion Engineered Carbons SA (0OE) | $99.89 Million | 80.26% | 10.70x | $327.05 Million |
| COVESTRO AG SP.ADR 1/2 (1CO1) | $6.62 Billion | -2.99% | 1.06x | $11.11 Billion |
| H&R GmbH & Co. KGaA (2HRA) | $471.16 Million | 9.06% | 1.04x | $183.88 Million |
| LOOP INDUSTRIES DL-001 (3L9) | $33.74 Million | -63.14% | 0.20x | $58.01 Million |
| Dotz Nano Ltd (57N) | $43.00K | -322.48% | 4.56x | $4.51 Million |
| TIDEWATER RENEWABLES LTD (7GZ) | $550.12 Million | 4.72% | 0.81x | $233.52 Million |
| DIRECTA PLUS PLC LS-0025 (88K) | $10.83 Million | -44.54% | 0.53x | $2.35 Million |
| TEKNA HOLDING ASA NK 2 (8VB) | $55.90 Million | -19.76% | 0.30x | $67.10 Million |
About INNO-GENE SA ZY -10
HyEnergy S.A. provides genetic diagnostic solutions in Poland. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of solid tumors. In addition, it provides DNA analysis and genetic diseases diagnostic service based on NGS technology. HyEnergy S.A. was formerly known as Inno-Gene S.A. and changed its name to HyEnergy S.A. in October 2024. … Read more